Definium Therapeutics (DFTX) Enterprise Value (2022 - 2026)
Definium Therapeutics (DFTX) posted quarterly Enterprise Value of -$368.1 million for Q1 2026, down 73.27% year-over-year from -$1.4 billion in Q1 2025, and up 10.02% quarter-over-quarter from -$409.1 million in Q4 2025.
Definium Therapeutics (DFTX) Enterprise Value (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Enterprise Value for 5 consecutive years, with -$368.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 73.27% year-over-year to -$368.1 million; the TTM figure through Mar 2026 stood at -$368.1 million (down 73.27% YoY), while the FY2025 annual figure was -$409.1 million, down 50.68% from the prior year.
- Enterprise Value advanced to -$368.1 million in Q1 2026 per DFTX's latest filing, from -$409.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$96.7 million in Q4 2023 and bottomed at -$409.1 million in Q4 2025.
- Historically, Enterprise Value has averaged -$204.6 million across 5 years, with a median of -$194.3 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 180.77% — and 2025, when it grew 29.2%.
- Definium Therapeutics' Enterprise Value stood at -$131.7 million in 2022, then gained by 26.58% to -$96.7 million in 2023, then plunged by 180.77% to -$271.5 million in 2024, then sank by 50.68% to -$409.1 million in 2025, then rose by 10.02% to -$368.1 million in 2026.
- Business Quant data shows DFTX's Enterprise Value at -$368.1 million in Q1 2026, -$409.1 million in Q4 2025, and -$209.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | -1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.08 Bn |
| Mar 31, 2026 | -368.10 Mn |
| Dec 31, 2025 | -409.10 Mn |
| Sep 30, 2025 | -209.06 Mn |
| Jun 30, 2025 | -179.50 Mn |
| Mar 31, 2025 | -212.44 Mn |
| Dec 31, 2024 | -271.50 Mn |
| Sep 30, 2024 | -295.28 Mn |
| Jun 30, 2024 | -243.13 Mn |
| Mar 31, 2024 | -249.10 Mn |
| Dec 31, 2023 | -96.70 Mn |
| Sep 30, 2023 | -115.30 Mn |
| Jun 30, 2023 | -110.70 Mn |
| Mar 31, 2023 | -122.30 Mn |
| Dec 31, 2022 | -131.70 Mn |
| Sep 30, 2022 | -154.52 Mn |
| Jun 30, 2022 | -105.74 Mn |